Palantir reports strong Q3 results, raises guidance, and highlights investor interest amid an AI-driven earnings season.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
US consumer confidence falls to three-month low amid job and price concerns, reflecting ongoing anxiety about tariffs, inflation, and trade tensions.
Palantir reports strong Q3 results, raises guidance, and highlights investor interest amid an AI-driven earnings season.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
US consumer confidence falls to three-month low amid job and price concerns, reflecting ongoing anxiety about tariffs, inflation, and trade tensions.